Диссертация (1139978), страница 32
Текст из файла (страница 32)
// Neurology. – 1988–Vol.38 – p. 680–684.63.Cummings J.L. Theneuropsychiatric inventory: comprehensive assessment ofpsyhopathology in dementia / Cummings J.L. Mega M., Gry K. et al. // Neurolоgy.–1994. – Vol. 44. – p.2308-2314.64.Dalrymple-Alford J.C. Characterizing mild cognitive impairment in Parkinson’sdisease / Dalrymple-Alford J.C., Livingston L., MacAskill M.R., Graham C.,Melzer T.R., Porter RJ, et al.
//Mov Disord – 2011.–Vol. 26 – p. 629-36.65.Del Tredici K.Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia / Del Tredici K., Braak H.// J Neurol Neurosurg Psychiatry – 2013.– Vol. 84 – p.774-83.66.Devos D. Comparison of desipramine and citalopram treatments for depression inParkinson’s disease: a double-blind, randomized, placebo-controlled study /Devos D., Dujardin K., Poirot I., et al. //Mov.
Disord. – 2008. – Vol.23.– р.850857.67.Dubois B. Diagnostic proceduresfor Parkinson’s disease dementia: recommendations from the movement disorder society task force./ Dubois B., Burn D., GoetzC., et al // Mov. Disord. – 2007 – Vol. 22 – p. 2314–2324.18468.Dubois B. Research criteria forthediagnosis of Alzgeimer’s disease: revising ofthe NINCDS-ADRDA criteria / Dubois B., Feldman H. H., Jacova C. et al. //Lancet neurol.
– 2007. – Vol.608. – p. 734-746.69.Dubois В. The FAB: frontal assessment battery at bedside / Dubois В., Slachevsky A.,Litvan I., Pillon B // Neurology. – 2000. – Vol. 55. – p.1621-1626.70.Dubois B. Donepezil in Parkinson’s disease dementia: a randomized, doubleblind efficacy and safety study / Dubois B., Tolosa E., Katzenschlager R., et al. //Mov Disord. – 2012. – Vol.27. – р.1230-1238.71.Duarte J. Thenatural history of Parkinson’s disease in the province of Segovia:mortality in a longitudinal study (20-year follow- up) / DuarteJ., Garcia O.L.,Mendoza A., Claveria L.E. // Acta Neurol Scand.
– 2013. – Vol.127.– р.295–300.72.Edison A.U. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography / Edison A.U.,Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N.//Neurol NeurosurgPsychiatry.–2008.–79(12). – р.1331.73.Ehrt U.Use o drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study / Ehrt U., Broich K., Larsen J.P., Ballard C.,Aarsland D.// J Neurol Neurosurg Psychiatry. – 2009.– Vol.
87.–р. 18674.Engelborghs S.Neuropsychiatric symptoms of dementia: cross-sectional analysisfrom a prospective, longitudinal Belgian study / Engelborghs S. Maertens K.,Nagels G., et al. //Int J Geriatr Psychiatry. – 2005. –Vol.20.–р.1028–1037.75.Emre M. Dementia Associated with Parkinson’s Disease / Emre M. // LancetNeurology.–2003.–Vol.2–р.229-37.76.Emre M.,Aarsland D., Brown R. et al. Clinical diagnostic criteria for dementiaassociated with Parkinson disease / Emre M.,Aarsland D., Brown R. et al. // Mov.Disord. 2007–Vol.22.–р.1689-1707.77.Emre М. Cognitive Impairment and Dementia in Parkinson’s Disease / Emre М.Ford P.J.
// Practical Issues and ManagementMovement Disorders. – 2014.–№5.–Vol. 29.–р.13118578.Erkinjuntti T. Reseach criteria for subcortical vascular dementia in clinical trials /Erkinjuntti T., Inzitary D., Pantonii L., et al.//J Neural. Transm. – 2000. – Vol 59(suppl 1) – p.23-30.79.Fahn S. The UPDRS development committee, in Recent Developments in Parkinson’s Disease / Fahn S., Elton R. //Macmillan Healthcare Information, Florham Park, NJ, USA–1987.–p.
153–163.80.Fahn S. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson’s disease and their role in akinesia, rigidity, chorea, andtremor / Fahn S., Libsch L.R., Cutler R.W. // J NeurolSci .–1971. –Vol.. 14 –p.427-55.81.Farlow M.R. Modern Hypothesis:The Distinct Pathologies of Dementia Associated with Parkinon s Disease versus Alzhaimers Deases / Farlow M.R. CummingsJ.A // Dement Geriatr Cogn Disord.–2008 – Vol.25– p.301-308.82.Fazekas F. Pathologic correlates of J incidental MRI white matter signal hyperintensities / Fazekas F., Kleinert R., Offenbacher H.
et al. // Neurology. – 1998.–Vol.43–р.1683-1689.83.Fenelon G. Hallucinations in Parkinson's disease: prevalence, phenomenologyand risk factors / Fenelon G., Mahieux F., Huon R., Ziegler M. // Brain –2000.–Vol.123. -p.733–745.84.Fernandez H.H. Quetiapine improves visual hallucinations in Parkinson diseasebut notthrough normalization of sleep architecture: results from a double-blindclinical-polysomnography study. / Fernandez H.H., Okun M.S., Rodriguez R.L.,et al.
//Int J Neurosci. –2009. – Vol.119 –р. 2196-2205.85.Folstein M. F. Mini-Mental State: Apracticalguaidefor grading themetal. stateofpatients for theclinic / Folstein M. F. ,Folstein S.E., Mc HughP.R.//J. Psych.Res. – 1975. – Vol .12. – p.189-198.86.Foltynie T. The cognitive ability of an incident cohort ofParkinson’s patients inthe UK.
The CamPaIGN study / Foltynie T., Brayne C.E.G, Robbins T.W., Barker R.A. // Brain.– 2004. – Vol.. 127 – p. 550-60.18687.Francis P.T. Biochemical and pathological correlates of cognitiveand behaviouralchange in DLB/PDD / Francis P.T. // J Neurol.– 2009 – 256 Supp 3 – р.280–5.88.Fuller P.M.Reassessment of the structural basisof the ascending arousal system/Fuller P.M., Fuller P., Sherman D., Pedersen N.P., Saper C.B., Lu J. //J CompNeurol.–2011.–Vol. 519. –p. 933–56.89.Galvin J.E.Clinical phenotype of Parkinson disease dementia /Galvin J.E., PollackJ.,Morris J.C.
// Neurology.– 2006.– 67(9). – р. 1605-1611.90.Garcia-GarciaD. Posterior parietooccipital hypometabolism may differentiatemild cognitive impairment from dementia in Parkinson’s disease /GarciaGarciaD., Clavero P.,at all.// Eur J Nucl Med Mol Imaging –2012.–Vol.39 – р.1767–77.91.Girotti F.
Dementia and cognitive impairment in Parkinson's disease. J Neurol.Neurosurg / Girotti F., Soliveri P., Carella F., et al. //Psychiatry –1988.–Vol.51 –р.1498–1502.92.Goldman J.G. Visuoperceptive region atrophy independent of cognitive status inpatients with Parkinson’sdisease with hallucinations / Goldman J.G., StebbinsG.T., Dinh V., Bernard B., Merkitch D., Detoledo-Morrell L., et al.// Brain.–2014.–Vol. 137 (Pt 3)–p.849-59.93.González-Redondo R. Neural substrates of cognitive subtypes in Parkinson’s disease: a 3-year longitudinal study / González-Redondo R, García-García D, Clavero P, etal.// Brain.–2014.–Vol.137.–р.
2356–67.94.Gratwicke J. Parkinson'sdiseasedementia: aneuralnetworksperspective / Gratwicke J., JahanshahiM., Foltynie T. // Brain–2015–138 (6) –p. 1454-1476.95.Grossia D. Apathy and related executive syndromes in dementia associated withParkinson’s disease and in Alzheimer’s disease /Grossia D.,SantangeloaG.,Barbaruloa A.M. // Behavioural Neurology.
– 2013–(27).–p. 515–522.96.Hall H. Hippocampal Lewy pathology and cholinergic dysfunction are associatedwith dementia in Parkinson's disease. Brain: / Hall H., Reyes S., Landeck N.,Leanza G.//A Journal Of Neurology [Brain].–2014. –Sep. –Vol. 137 (Pt 9).–pp.2493-508.18797.Halliday G. The progression of pathology in longitudinally followed patients withParkinson’s disease / Halliday G., Hely M., Reid W., Morris J.// Acta Neuropathol–2008,–Vol.115–р.409–415.98.Hattori T.
Cognitive status correlates with white matter alteration in Parkinson’sdisease / Hattori T., Orimo S., Aoki S., Ito K., Abe O., Amano A., et al. // HumBrain Mapp – 2012.–Vol. 33.–p.727-39.99.Haugarvoll K. The influence of cerebrovascular risk factors on incident dementiain patients with Parkinson’s disease / Haugarvoll K., Aarsland D., WentzelLarsen T., Larsen J.P.// Acta Neurol Scand.
– 2005.–Vol.112. – p.386– 390.100. Hely M.A. The Sydney multicenter study of Parkinson's disease: the inevitabilityof dementia at 20 years / Hely M.A, Reid W.G., Adena M.A.// Mov Disord. –2008. –Apr 30.–Vol.23(6).–р. 837-44.101. Henderson J.M. Parkinson’s disease with late Pick’s dementia /Henderson J.M.,Gai W.P., Hely M.A., Reid W.G., Walker G.L.,Halliday G.M. //Mov. Disord. –2001–Vol.16–р. 311–9102. Henry J.D.Verbal fluency deficits in Parkinson’s disease: a meta-analysis / HenryJ.D., Crawford J.R.
// J IntNeuropsychol Soc.–2004.–Vol.. 10.–p. 608-22.103. Hirono N. Neuropsychiatric features in dementia with lewy bodies and Alzheimer's disease / Hirono N., Mori E., Imamura T., Shimomura T., Hashimoto M. //Brain Nerve–1998. – Vol.50.–р. 45–49.104. Hobson P. Mild cognitive impairment in Parkinson's disease and its progressiononto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int/Hobson P., Meara J // J Geriatr Psychiatry–2015–Vol.30–р.1048–1055105.
Hoehn M.M. Parkinsonism: Onset, Progression and mortality / Hoehn M.M.,YarhH.D. // Neurology.–1967. – Vol 17.–p. 427-442106. Huang C. Metabolic brain networks associated with cognitive function in Parkinson’s disease / Huang C., Mattis P., Tang C., Perrine K., Carbon M., Eidelberg D.//Neuroimage.–2007.–Vol. 34.–p. 714-23.188107. Hughes T.A.A 10-year study of the incidence of and factors predicting dementiain Parkinson’s disease / Hughes T.A., Ross H.F., Musa S., Bhattacherjee S., Nathan R.N., Mindham RH et al //Neurology. – 2000.–Vol.54.–р. 1596–1602.108. Ibarretxe-Bilbao N.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
